2006
DOI: 10.1016/j.taap.2005.09.011
|View full text |Cite
|
Sign up to set email alerts
|

Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methycholanthrene

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
33
2

Year Published

2009
2009
2015
2015

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 51 publications
(39 citation statements)
references
References 32 publications
3
33
2
Order By: Relevance
“…In other studies, AhR ligands have been found to activate ER-mediated transcriptional activity without a requirement for the AhR (Abdelrahim et al, 2006;Shipley and Waxman, 2006). Abdelrahim et al (2006) reported that AhR ligands 3-methylcholanthrene and 3,3Ј,4,4Ј,5-pentachlorobiphenyl were capable of activating ERs in MCF7 breast cancer cells, whereas Shipley and Waxman (2006) found that 3-methylcholanthrene but not 3,3Ј,4,4Ј,5-pentachlorobiphenyl or TCDD functioned as an ER agonist in Ishikawa uterine cancer cells. In another study, Boverhof et al (2006) reported that TCDD treatment of ovariectomized mice altered the expression of numerous uterine genes that were comparably regulated by 17␣-ethynylestradiol.…”
Section: Downloaded Frommentioning
confidence: 97%
See 1 more Smart Citation
“…In other studies, AhR ligands have been found to activate ER-mediated transcriptional activity without a requirement for the AhR (Abdelrahim et al, 2006;Shipley and Waxman, 2006). Abdelrahim et al (2006) reported that AhR ligands 3-methylcholanthrene and 3,3Ј,4,4Ј,5-pentachlorobiphenyl were capable of activating ERs in MCF7 breast cancer cells, whereas Shipley and Waxman (2006) found that 3-methylcholanthrene but not 3,3Ј,4,4Ј,5-pentachlorobiphenyl or TCDD functioned as an ER agonist in Ishikawa uterine cancer cells. In another study, Boverhof et al (2006) reported that TCDD treatment of ovariectomized mice altered the expression of numerous uterine genes that were comparably regulated by 17␣-ethynylestradiol.…”
Section: Downloaded Frommentioning
confidence: 97%
“…Concerning proestrogenic effects, Ohtake et al (2003) reported that AhR ligand treatment can induce ER-mediated transcription through the formation of an AhR ⅐ ARNT ⅐ ER complex (Brosens and Parker, 2003). In other studies, AhR ligands have been found to activate ER-mediated transcriptional activity without a requirement for the AhR (Abdelrahim et al, 2006;Shipley and Waxman, 2006). Abdelrahim et al (2006) reported that AhR ligands 3-methylcholanthrene and 3,3Ј,4,4Ј,5-pentachlorobiphenyl were capable of activating ERs in MCF7 breast cancer cells, whereas Shipley and Waxman (2006) found that 3-methylcholanthrene but not 3,3Ј,4,4Ј,5-pentachlorobiphenyl or TCDD functioned as an ER agonist in Ishikawa uterine cancer cells.…”
Section: Downloaded Frommentioning
confidence: 99%
“…TransIT-LT1 was preincubated with serum free medium for 5 min and added to the Hoechst dye-DNA mix and further incubated for 15 min. The mix was then added equally to each well to be transfected (Shipley and Waxman, 2006). Transfections were performed using the following amounts of plasmid DNA per well of a 48-well tissue culture plate: 10 ng of receptor plasmid (AR, ERα, ERβ, TRβ, PR-B, RARα, RARβ or RARγ), 90 ng of reporter plasmid (pPB-luc, ERC3-luciferase, pTK-TR(DR4) 3 , progesterone receptor reporter plasmid or pGL3-β-RARE-luc), 20 ng of pSV-βgal (for normalization of luciferase activity) and 130 ng salmon sperm DNA.…”
Section: Plasmidsmentioning
confidence: 99%
“…DIM has been reported not only to inhibit estrogenic responses (26) but also to activate ERα in the absence of 17β-estradiol (E 2 ) via protein kinase A-mediated phosphorylation (27,28). Although AHR agonists such as 3-methylcholanthrene have been reported to enhance ER-dependent responses (29,30), two independent studies have shown that the estrogenic activity of 3-methylcholanthrene is independent of AHR (31,32). Moreover, a number of AHR ligands have been shown to directly activate ERα, defining a new class of bifunctional AHR/ERα agonists (33,34).…”
Section: Introductionmentioning
confidence: 99%